scholarly journals Insulin-like growth factor binding protein-1 regulates HIF-1α degradation to inhibit apoptosis in hypoxic cardiomyocytes

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Xiaoyan Tang ◽  
Huilin Jiang ◽  
Peiyi Lin ◽  
Zhenhui Zhang ◽  
Meiting Chen ◽  
...  

AbstractHypoxia is important in ischemic heart disease. Excessive Insulin-like growth factor binding protein-1 (IGFBP-1) amounts are considered to harm cardiomyocytes in acute myocardial infarction. However, the mechanisms by which IGFBP-1 affects cardiomyocytes remain undefined. The present study demonstrated that hypoxia up-regulates IGFBP-1 and HIF-1α protein expression in cardiomyocytes. Subsequent assays showed that IGFBP-1 suppression decreased HIF-1α expression and inhibited hypoxia-induced apoptosis in cardiomyocytes, which was reversed by HIF-1α overexpression, indicating that HIF-1α is essential to IGFBP-1 function in cellular apoptosis. In addition, we showed that IGFBP-1 regulated HIF-1α stabilization through interacting with VHL. The present findings suggest that IGFBP-1–HIF-1α could be targeted for treating ischemic heart disease.

2010 ◽  
Vol 208 (2) ◽  
pp. 593-598 ◽  
Author(s):  
Anwar Borai ◽  
Callum Livingstone ◽  
Majid Ghayour-Mobarhan ◽  
Ahmed Abuosa ◽  
Shahida Shafi ◽  
...  

Circulation ◽  
2002 ◽  
Vol 106 (8) ◽  
pp. 939-944 ◽  
Author(s):  
Anders Juul ◽  
Thomas Scheike ◽  
Michael Davidsen ◽  
Jesper Gyllenborg ◽  
Torben Jørgensen

2016 ◽  
Vol 13 (4) ◽  
pp. 307-311 ◽  
Author(s):  
Lisa Arnetz ◽  
Camilla Hage ◽  
Kerstin Brismar ◽  
Sergiu-Bogdan Catrina ◽  
Anna Norhammar ◽  
...  

Purpose: To investigate whether sitagliptin affects copeptin and osmolality, suggesting arginine vasopressin activation and a potential for fluid retention, compared with placebo, in patients with a recent acute coronary syndrome and newly discovered type 2 diabetes or impaired glucose tolerance. A second aim was to confirm whether copeptin correlated with insulin-like growth factor binding protein-1. Methods: Fasting blood samples were used from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction trial, in which patients recently hospitalized due to acute coronary syndrome and with newly detected abnormal glucose tolerance were randomized to sitagliptin 100 mg once daily ( n = 34) or placebo ( n = 37). Copeptin, osmolality and insulin-like growth factor binding protein-1 were analysed at baseline and after 12 weeks. Results: Copeptin and osmolality were unaffected by sitagliptin. There was no correlation between copeptin and insulin-like growth factor binding protein-1. Conclusion: Sitagliptin therapy does not appear to be related to activation of the arginine vasopressin system.


2019 ◽  
Vol 64 (1) ◽  
pp. 195-201 ◽  
Author(s):  
Anna Lisowska ◽  
Przemysław Święcki ◽  
Małgorzata Knapp ◽  
Monika Gil ◽  
Włodzimierz J. Musiał ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document